Alumis’ Post

We are excited to announce that Länssjukhuset Ryhov Jönköping has commenced participation in the groundbreaking BROKEN-SWEDEHEART study, in collaboration with esteemed Professor Elmir Omerovic. This multinational, multicentre, registry-based, open-label, randomized controlled trial focuses on optimizing pharmacological treatment for Takotsubo syndrome, also known as Broken Heart Syndrome. The study, funded by the Swedish Research Council and ALF Gothenburg, consists of two parallel parts. The first part investigates whether treatment with adenosine and dipyridamole accelerates cardiac recovery and improves clinical outcomes compared to standard care. The second part evaluates the efficacy of apixaban in reducing the risk of thromboembolic events compared to no anticoagulant therapy. We are proud to contribute to this vital research, which aims to enroll more than 500 participants. We are optimistic that the study will yield positive results, significantly advancing our understanding and treatment of Takotsubo syndrome, ultimately leading to better patient outcomes. #MedicalResearch #BROKENSWEDEHEART #LänssjukhusetRyhov #SahlgrenskaUS #ElmirOmerovic #TakotsuboSyndrome #RegionJönköpingslän

🌎🔬 Don’t Miss AMRA Medical at ICFSR 2024! 🔬🌎 This week, the AMRA Medical team will be in attendance at the 14th annual International Conference on Frailty and Sarcopenia Research (ICFSR), where our scientists will be showcasing their latest insights into muscle composition's critical role in various health outcomes. The presentations demonstrate the utility of AMRA's MRI-based body composition analysis platform, AMRA® Researcher, in delivering novel biomarkers that describe overall muscle health. This innovative approach is transforming muscle composition research by enabling more personalized insights on function and performance. By advancing disease research in neuromuscular, metabolic diseases, and beyond, AMRA Medical continues to lead with cutting-edge MRI-powered analyses, offering more personalized insights for researchers, patients, and providers alike. Stay tuned for more updates on how we're advancing disease research with our precision imaging platform in sarcopenia and beyond! To get in touch or if you are attending and want to meet us at ICFSR, reach out to info@amramedical.com. #ICFSR2024 #AMRAMedical #MuscleComposition #ChronicKidneyDisease #Sarcopenia #precisionmedicine #neuromusculardisease #MRI #clinicalresearch

If you are attending #NeuPSIG2023, do say hello to our Snr. Medical Director Marco Calabresi, who brings years of in-depth experience in clinical neuroscience across medical, scientific and operational functions. DM me if you'd like to have a chat, don't miss out on this opportunity! #clinicaldevelopment #neurology #neuroscience

We are excited to share that the Zamplo team is attending the 30th annual International Society for Quality of Life Research (ISOQOL) Conference! ISOQOL creates a global space for researchers, clinicians, health care professionals, industry professionals, consultants, and patient research partners advancing health related quality of life research (HRQL) to come together to discuss the patient perspective to health research, care and policy. This year's conference will focus on identifying barriers that limit the use of PROs in patient care and work towards forming new practical solutions. The Zamplo team will be presenting “Radiation PATH: Evaluating A Mobile Health-Based Radiation Oncology Patient Assessment Tool” at the conference. To learn more about how Zamplo Research can be used to advance HRQL clinical research and care, visit https://hubs.ly/Q024GtHK0 #healthresearch #clinicalresearch #PROMs #PROs #datacollection #patientengagement #researchparticipant #qualityoflife #QoL #ISOQOL #ePROS #patientreportedoutcomes #clinicalcare

📈 LiverPRO shows an 86% prognostic accuracy validated in +450,000 individuals We are happy to share that we will present our prognostic results on LiverPRO at the EASL Congress 2024. Come by our poster: “LiverPRO outperforms FIB-4 at predicting liver-related events in a cohort of 457.152 individuals” … and lets have a discussion around the benefits and need for early detection and accurate prognosis of at-risk patients. In our study, we compared the effectiveness of LiverPRO and FIB-4 in predicting liver-related events – showing an 86 % prognostic accuracy of LiverPRO. The research is based on the UK Biobank dataset with 457.152 individuals – a general UK patient population aged 40-69. Visit our poster (#FRI-045) on June 7th at the EASL Congress 2024 to explore our results in detail. Want to know more or chat about the findings? Reach out to our CSO Katrine Prier Lindvig! Co-authored by: Katrine Prier Lindvig P Lindvig, Sören Möller, Katrine H Thorhauge, Johanne K Hansen, Camilla D Hansen, Stine Johansen, Helle L Schnefeld, Mads Israelsen, Peter Andersen, Ida Villesen, Katrine T Bech, Nikolaj Torp, Aleksander Krag, Maja Thiele. Check out our other poster for EASL: https://lnkd.in/d5vke6aQ   #EASLCongress2024 #EASLposter #datadrivendiagnostics #steatoticliverdisease

Kudos to National Center for Advancing Translational Sciences (NCATS) for organizing an exciting #rarediseaseday2024 that featured many inspiring stories from patients, researchers, and clinicians. Our founder, Dr. Anne Chiaramello, Deputy Clinical Director Dr. Andrea Gropman and Deputy Scientific Director Dr. Martine Uittenbogaard attended; and all three walked away with real information that will be useful in NCATS funded clinical trial for two rare mitochondrial diseases. We will be sharing more insights soon, including a fascinating pictorial of the convoluted, and often frustrating, rare disease patient journey, presented by Dr. Kimberly Moran, PhD, MBA. Dr. Dominique Pichard's talk on #NCATS mission encapsulated the progress thus far accomplished for rare diseases by creating a seamless interface among patient advocacy groups, researchers, and clinicians to improve diagnosis and augmenting the number of treatments in the #drugdevelopment. What an inspirational day at The National Institutes of Health! Many thanks to Dr. Joni L Rutter, Director of #NCATS, and Dr. Monica Bertagnolli, #NIH Director, for shining the light on patients living with a #raredisease and their commitment to find a cure for #rarediseases. #rarediseaseawareness #mitochondrialdisease #lhonplus #melas #clinicaltrials #personalizedmedicine

Advances in new treatments, innovative research and OCT technology—like Heidelberg Engineering’s ANTERION®—are contributing to earlier detection of glaucoma. The Heidelberg Engineering team will be at Booth #23 at APGC 2024 in Manila, Philippines, from May 24-26 with their glaucoma toolkit—so stop by and see for yourself how you can optimize glaucomatous disease diagnosis, improve clinical workflow and effectively manage patients! SPECTRALIS® Glaucoma Module Premium Edition provides clinicians with a comprehensive set of tools for the assessment of structural loss that is characteristic of glaucoma—while ANTERION® supports with anterior segment OCT images for precise measurements that provide valuable diagnostic insights for glaucoma specialists. UNCOVER MORE:  https://lnkd.in/gsBeg7VT https://lnkd.in/gPKyrDks See you at APGC 2024! #glaucoma #SPECTRALIS #ANTERION #APGC #MediaMICE

🔎Exiting Advancements in TAVR Research! 🌎 Our recent study at the Mayo Clinic (Rochester) sheds light on post-TAVR stroke. • 📊 Among 2775 TAVR patients, those with a bovine aortic arch (common origin of carotid arteries) had a 3.6% incidence of periprocedural stroke, compared to 1.7% in non-bovine cases. • 📈 Over a median 2.7 years follow-up, post-TAVR stroke incidence was 10.5% in patients with a bovine arch, significantly higher than the 5.0% in non-bovine cases. • ❗️A bovine aortic arch is independently associated with a significantly higher risk of periprocedural (OR: 2.16) and long-term (HR: 2.17) stroke after TAVR. • 💡This insight is vital for refining patient risk assessment and advancing tailored strategies. Check out the entire publication here: https://lnkd.in/gWSCb4eh

How is Providence transforming healthcare through research? By pursuing the promise of genomic medicine for all, helping bring new medical devices and technologies to market, advancing personalized treatments for cancer and other diseases, reshaping standards of care and so much more. Learn about our research and its impact in the new 2023 Providence Research Network Annual Report.      #thefutureofhealth #research #healthcaretransformation #clinicaltrials      https://lnkd.in/ghDjDMiW 

Register for the incoming multidisciplinary webinar: "GET-NET: MDT" Wednesday, May 15, 18:00 CEST Speakers: Massimo Falconi, Milan/IT; Francesco Panzuto, Rome/IT; Andrea Laghi, Rome/IT; Damiano Caruso, Rome/IT Moderator: Evangelos Chartampilas, Thessaloniki/GR https://lnkd.in/dTnQvAy Here are some recommended articles for you to review before our upcoming regular webinar! - JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis  https://lnkd.in/epacaT5c - Prognostic value of CT characteristics in GEP-NET: A systematic review. https://lnkd.in/exQQfuM3 - What have we learnt from the past-would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022? https://lnkd.in/e4zGc5Tg This webinar is open to all ESOI members in good standing:  https://lnkd.in/ebvwASg8 #ESOI #multidisciplinary #oncologicimaging